NCT05112445View on ClinicalTrials.gov

"Retinal Ischemia Characterization in Diabetes - RICHARD"

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

March 30, 2022

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Diabetic Retinopathy
Trial Locations (1)

3000-548

AIBILI-CEC (AIBILI- Clinical Trials Centre), Coimbra

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Association for Innovation and Biomedical Research on Light and Image

OTHER

NCT05112445 - "Retinal Ischemia Characterization in Diabetes - RICHARD" | Biotech Hunter | Biotech Hunter